First non-melanoma skin cancer patients treated with the Rhenium-SCT® in Germany

HANAU, Germany - EntSun -- October 4, 2019; Hanau, Germany - OncoBeta®, a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), announced today, that Dr. Lutz-Hendrik Holle, Medical Director of the interregional professional association for nuclear medicine in Hanau, has accomplished the first Rhenium-SCT® (Skin Cancer Therapy) treatment in Germany. This state-of-the-art technology of local radionuclide therapy offers a painless and non-invasive treatment option for patients with basal cell carcinoma and squamous cell carcinoma (BCC and SCC) and the interregional professional association for nuclear medicine Hanau is the first center in Germany that offers the Rhenium-SCT®.

With approximately 50.000 outpatient examinations annually, the interregional professional association for nuclear medicine Hanau is one of the biggest nuclear medicine service providers in Hesse. The offered services include a variety of different modern treatment and diagnostic methods. The key argument for the expansion of the spectrum was that the Rhenium-SCT® is a new, painless and highly efficient treatment option that also delivers excellent cosmetic results. Besides being a painless alternative to other procedures, the Rhenium-SCT® also allows the treatment of numerous NMSC lesions consecutively in a single session, which was already realized during the first treatment in Hanau. This has also attracted international attention so that an American patient travelled to Hanau for the treatment.

"This therapy is particularly suitable for tumor localizations where good cosmetic results are to be achieved. The fact that the treatment is completely painless and can be performed in just one session is a great advantage", says Dr. Holle, Medical Director of Nuclear Medicine in Hanau.

More on EntSun News

• Evolve IP Offers Rapid Deployment of Desktop as a Service to Ingram Micro Partners
• Santa Claus and Red Skelton Bring Back Meaning to The Pledge of Allegiance
• 626 acquires the assets of Innovatus CR and DR Business. The World Slows Down. We Move Faster
• R+M Development Closes on Refinance of Student Housing Project Amidst Pandemic
• The Grand Indian Route Launches Golden Triangle tour Package

"We are very happy and proud to be able to offer our revolutionary treatment to patients in Germany now. The treatment center in Hanau is an excellent partner for patients in the fight against NMSC", said Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH. "Unfortunately, Germany is one of the countries that has experienced a drastic increase in newly diagnosed NMSC cases in recent years. Our highly qualified team strives to provide physicians and patients with a non-invasive and affordable solution to treat NMSC, while focusing on the needs of the patient. "

The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. In certain analyzed areas of Germany there was an increase in the incidence between the year 2005 and the year 2014 by about 30%¹. To serve the increasing medical need for innovative therapies in this field and to improve the quality of patients' lives, OncoBeta® GmbH has developed its innovative Rhenium-SCT® which only require a single application in most of the cases, applied in one single session with excellent aesthetic outcomes.

About the Rhenium-SCT® (Skin Cancer Therapy)
The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium-SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium-SCT® compound never comes in direct contact with the patients' skin. Most cases of non-melanoma skin cancers (basal cell carcinomas and squamous cell carcinomas) can be treated using the Rhenium-SCT® with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.

More on EntSun News

• Teenage mariachi ensemble records album during pandemic, keeping social distancing guidelines
• Getman Takes his Popular Book Fairs into the Virtual World Transforming the Way Buyers Meet Sellers of Rare Books, Maps, Prints and Ephemera
• Teleroute, Part of Alpega Group, launches an API Interface and a new Mobile App to help their growing number of customers work even more efficiently
• How to change gmail password?
• How to recover yahoo password?

About OncoBeta® GmbH
OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. The Rhenium-SCT® is European CE certified and is filed for regulatory approval in several other countries outside the European Union.

Find out more about the Rhenium-SCT® at https://www.oncobeta.com

Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: ttps://www.facebook.com/OncoBeta/

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta®'s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta®'s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Source (in german language)
1: Leitlinienprogramm Onkologie; S3 Leitlinie Aktinische Keratose und Plattenepithelkarzinom der Haut; Version 1.0; Juni 2019